




A**B****C**

Supplementary Figure S2.

PBMC were analyzed at indicated timepoints by high-dimensional single cell mass cytometry. **(A)** Manual gating was performed to identify immune subsets. Fold change in CD3⁺ T cells, CD3⁺CD4⁺ T cells, CD3⁺CD8⁺ T cells, CD3⁺CD4⁺CD25⁺CD127^{low}Foxp3⁺ Treg cells, CD19⁺ B cells, CD14^{neg}HLA-DR⁺ dendritic cells, CD14⁺ monocytes and CD16⁺CD56⁺ NK cells. **(B)** Quantification of changes in B cell frequency. **(C)** Comparison of CD45⁺ Phenograph defined clusters at baseline (pre), after galunisertib (d15-25) and after SBRT (d28). Wilcoxon matched-pairs tests were performed **(B)**. 2-way ANOVA with Tukey's multiple comparisons was performed **(C)**. *, p < 0.05. n.s., not significant.